About LEAD Therapeutics
LEAD Therapeutics is a company based in San Bruno (United States) founded in 2006 was acquired by BioMarin Pharmaceutical in February 2010. It operates as a B2B. LEAD Therapeutics has raised $20 million across 2 funding rounds from investors including BioMarin Pharmaceutical, ProQuest Investments and Mustang Ventures. LEAD Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter San Bruno, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20 M (USD)
in 2 rounds
-
Latest Funding Round
$3 M (USD), Series A
Jun 02, 2009
-
Investors
BioMarin Pharmaceutical
& 3 more
-
Employee Count
Not available
-
Acquired by
BioMarin Pharmaceutical
(Feb 04, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of LEAD Therapeutics
LEAD Therapeutics has successfully raised a total of $20M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in LEAD Therapeutics
LEAD Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include BioMarin Pharmaceutical, ProQuest Investments and Mustang Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
VC firm focusing on life science sector
|
Locked | Locked | Locked |
Investor details for LEAD Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LEAD Therapeutics
Investment portfolio details for LEAD Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - LEAD Therapeutics
Detailed financials for LEAD Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lead Therapeutics Comparisons
Peer comparison for LEAD Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LEAD Therapeutics
LEAD Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of LEAD Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lead Therapeutics
Complete news archive for LEAD Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LEAD Therapeutics
LEAD Therapeutics was founded in 2006 and raised its 1st funding round 1 year after it was founded.
LEAD Therapeutics is headquartered in San Bruno, United States. It is registered at San Bruno, California, United States.
LEAD Therapeutics is a funded company, having raised a total of $20M across 2 funding rounds to date.
LEAD Therapeutics drug discovery company developing therapeutics for cancer and infectious diseases treatment, focusing on providing healthcare solutions, advancing biotech innovations, drug discovery, and therapeutics development. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
LEAD Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
LEAD Therapeutics has 4 investors. Key investors include BioMarin Pharmaceutical, ProQuest Investments, Mustang Ventures, and Pappas Capital.